On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series, with BAO PHARMA-B (02659) being added to the Hang Seng Composite Index. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this adjustment, the Shanghai and Shenzhen Stock Exchanges will correspondingly update the list of investable targets under the Hong Kong Stock Connect scheme. According to a big data forecast, BAO PHARMA is expected to be included in the Hong Kong Stock Connect, presenting a new development opportunity. The company's pipeline includes KJ017, China's first recombinant human hyaluronidase submitted for market approval, intended for large-volume subcutaneous drug delivery; KJ103, a globally first-in-class IgG-degrading enzyme with potential for "best-in-class" status in terms of low pre-existing antibodies and dosing frequency, targeting antibody-mediated autoimmune diseases; and SJ02, a long-acting follicle-stimulating hormone drug for assisted reproduction, which has already undergone collaborative validation. These three core products are either in the commercialization phase, under new drug application review, or in late-stage clinical trials in China, indicating BAO PHARMA's imminent transition from a purely R&D-focused stage to commercialization. Adjustments to the Hong Kong Stock Connect list have consistently served as a market indicator. If BAO PHARMA successfully gains inclusion, it is expected to significantly enhance the stock's liquidity and valuation premium, while also providing mainland investors with a new opportunity to precisely allocate capital to high-quality biopharmaceutical assets.